Crigler-Najjar Syndrome – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Crigler-Najjar
Syndrome – Pipeline Review, H1 2019” drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Crigler-Najjar Syndrome – Pipeline Review, H1 2019, provides an overview
of the Crigler-Najjar Syndrome (Genetic Disorders) pipeline landscape.

Crigler-Najjar syndrome is a severe condition characterized by high
levels of a toxic substance called bilirubin in the blood
(hyperbilirubinemia). Symptoms include yellow skin (jaundice) and yellow
in the whites of the eyes (icterus). It occurs when the enzyme that
normally converts bilirubin into a form that can easily be removed from
the body does not work correctly. Treatment includes phototherapy, liver
transplantation and blood transfusions.

Report Highlights

This latest pipeline guide Crigler-Najjar Syndrome – Pipeline Review, H1
2019, provides comprehensive information on the therapeutics under
development for Crigler-Najjar Syndrome (Genetic Disorders), complete
with analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.

The Crigler-Najjar Syndrome (Genetic Disorders) pipeline guide also
reviews of key players involved in therapeutic development for
Crigler-Najjar Syndrome and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in Phase
II, Preclinical and Discovery stages are 2, 2 and 1 respectively.
Similarly, the Universities portfolio in Phase II stages comprises 1
molecules, respectively.

Crigler-Najjar Syndrome (Genetic Disorders) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Crigler-Najjar Syndrome (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Crigler-Najjar
  Syndrome (Genetic Disorders) by companies and universities/research
  institutes based on information derived from company and
  industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Crigler-Najjar
  Syndrome (Genetic Disorders) therapeutics and enlists all their major
  and minor projects.
• The pipeline guide evaluates Crigler-Najjar Syndrome (Genetic
  Disorders) therapeutics based on mechanism of action (MoA), drug
  target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Crigler-Najjar Syndrome (Genetic Disorders)

Reasons to Buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Crigler-Najjar Syndrome (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Crigler-Najjar Syndrome (Genetic Disorders) pipeline depth and focus
  of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Companies Mentioned

• Audentes Therapeutics Inc
• International Stem Cell Corp
• Logicbio Therapeutics Inc
• Promethera Biosciences SA
• Selecta Biosciences Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/swc8l3

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Endocrine
and Metabolic Disorders Drugs